Condensed Consolidated Statement of Cash Flows $ in Thousands	9 Months Ended
	Dec. 31, 2016 USD ($)
Cash flows from operating activities:
Net loss	$ (61,766)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	6,781
Depreciation	9
Purchase of in-process research and development expense	13,117
Changes in the fair value of the warrant liability	28,815
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,153)
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc.	3,301
Other assets	(100)
Accrued expenses and accounts payable	3,461
Income tax receivable	(15)
Net cash used in operating activities	(7,550)
Cash flows from investing activities:
Purchase of property and equipment	(369)
Net cash used in investing activities	(369)
Cash flows from financing activities:
Cash proceeds from issuance of common shares in initial public offering, net of underwriting discount	202,275
Initial public offering costs paid	(2,091)
Cash capital contribution from Roivant Sciences Ltd.	1,036
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company	(979)
Net cash provided by financing activities	200,241
Net change in cash	192,322
Cash—beginning of period	0
Cash—end of period	192,322
Non-cash financing activities:
Deferred initial public offering costs, unpaid	220
Purchase of in-process research and development	13,117
Supplemental disclosure of cash paid:
Taxes	$ 55